in vitro News and Research

RSS

European collaboration to design a biomimetic bioartificial liver

Medicyte, The Electrospinning Company and the Universities of Manchester and Pisa launch a European wide unique project with the aim to design a biomimetic bioartificial liver (Re-Liver). The company GABO:mi ensures professional project management.

2 Jul 2012

Evolution of Advanced IVDs Conference to take place on September 19-20, 2012

IVD Technology Magazine announces the Evolution of Advanced IVDs Conference on September 19-20, 2012 at the San Diego Convention Center.

29 Jun 2012

RapidChek- SELECT Salmonella highly sensitive to the presence of S. Typhi vaccine in stool

Salmonella Typhi (S. Typhi) is the causative agent of typhoid fever, a serious health threat resulting in some 22 million new cases yearly and approximately 217,000 fatalities. A number of novel vaccine candidates using live attenuated strains of Salmonella are being developed, but care must be taken to ensure the bacteria are not excreted into the environment following vaccination.

29 Jun 2012

Nanosphere receives FDA marketing approval for Verigene GP Blood Culture Nucleic Acid Test

The U.S. Food and Drug Administration today allowed marketing of the first nucleic acid test that can identify 12 different bacterial types known to cause bloodstream infections.

28 Jun 2012

Data from Infinity’s IPI-145 pre-clinical study on inflammatory diseases

Infinity Pharmaceuticals, Inc. today reported preclinical data for IPI-145, the company's oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma. The data demonstrate potent PI3K-delta and -gamma inhibition in biochemical, cellular and whole blood assays and activity in multiple preclinical models of inflammatory disease, including rheumatoid arthritis and asthma.

28 Jun 2012

Sunshine Biopharma completes Adva-27a cytotoxicity study on multidrug-resistant lung cancer

Sunshine Biopharma Inc., a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has completed a cytotoxicity study of its lead compound, Adva-27a, in H69AR, a Multidrug Resistant Small Cell Lung Cancer cell line. Cytotoxicity studies measure the ability of a drug to destroy cancer cells in vitro.

27 Jun 2012

RXi Pharmaceuticals initiates RXI-109 Phase 1 trial to reduce surgical scars

RXi Pharmaceuticals Corporation today announced that it successfully initiated its first ever clinical study with an RNAi compound, RXI-109, using their proprietary self-delivering RNAi technology.

27 Jun 2012

HemoGenix receives first Master File Number from FDA CBER for HALO-96 PQR

HemoGenix announced today that FDA CBER has given HemoGenix its first Master File Number for an in vitro blood stem cell potency, quality and release assay (HALO-96 PQR) for cellular therapy products used for stem cell transplantation purposes. HALO-96 PQR is the first commercially available stem cell potency assay for cellular therapy products.

27 Jun 2012

Study: Fertility drug-conceived children are shorter on average

Among children born full term, those conceived with the help of fertility drugs are slightly shorter than naturally conceived children but overall are physically healthy, a new study finds. Results of the study will be presented Saturday at The Endocrine Society's 94th Annual Meeting in Houston.

26 Jun 2012

Teleflex announces acquisition of Semprus BioSciences

Teleflex Incorporated, a leading global provider of medical devices for critical care and surgery, announced it has acquired Semprus BioSciences, a biomedical company and spin out from Massachusetts Institute of Technology.

25 Jun 2012

Skin infections in AD patients linked to PMN impairment

Impairment of polymorphonuclear granulocytes among patients with atopic dermatitis may represent an additional cause of skin infections, suggest study findings.

22 Jun 2012

UC3M joins European research project on tuberculosis treatments

Scientists at the Carlos III University in Madrid (UC3M) are participating in a European research project designed to study tuberculosis treatments. The objective of the study is to improve diagnostic imaging technology in order to help develop new drugs to treat the disease.

22 Jun 2012

Selenium reduces Staph populations in medical implants

Selenium is an inexpensive element that naturally belongs in the body. It is also known to combat bacteria. Still, it had not been tried as an antibiotic coating on a medical device material. In a new study, Brown University engineers report that when they used selenium nanoparticles to coat polycarbonate, the material of catheters and endotracheal tubes, the results were significant reductions in cultured populations of Staphylococcus aureus bacteria, sometimes by as much as 90 percent.

22 Jun 2012

MAQUET's INTERGARD SYNERGY vascular graft receives CE mark

MAQUET Cardiovascular, LLC announced today that it has received CE mark for its INTERGARD SYNERGY vascular graft. This graft represents the next generation in antimicrobial grafts combining the well-known antimicrobial properties of silver acetate and triclosan.

19 Jun 2012

LDL particles may be a more accurate measure of early-stage atherosclerosis

LipoScience, Inc., today announced publication of a clinical study in the current issue of Atherosclerosis suggesting that low density lipoprotein (LDL) particles may be a more accurate measure of early-stage (subclinical) atherosclerosis than LDL cholesterol among retired National Football League (NFL) players.

19 Jun 2012

Life Technologies introduces three next generation genetic engineering kits

Life Technologies Corporation today announced the launch of three next generation GeneArt genetic engineering kits that allow molecular and synthetic biologists unprecedented speed, flexibility, precision, and efficiency for the seamless cloning, assembly, and editing of genetic material.

19 Jun 2012

Researchers identify commensal bacteria in the human intestine

Researchers at Baylor College of Medicine and Texas Children's Hospital have identified commensal bacteria in the human intestine that produce a neurotransmitter that may play a role in preventing or treating inflammatory bowel diseases such as Crohn's disease.

18 Jun 2012

New methods show signs of promise for successful IVF treatments

The success rate of in vitro fertilization (IVF) procedures still remains relatively low, at only around 30%. The high emotional, health and financial costs associated with having to undergo the procedure multiple times has driven the need to develop more efficient methods of assessing the development potential of embryos to ensure that only those with the highest potential are selected for IVF treatment.

13 Jun 2012

Long-lasting weekly fertility injections work as well as daily

New long-lasting weekly injections of fertility hormones are as safe and effective as standard daily injections, according to Cochrane researchers. The researchers compared weekly and daily hormone injections in a Cochrane systematic review and found no difference in pregnancies or serious side effects between the two regimens.

13 Jun 2012

IVF linked to increased relapse rate among MS patients

In vitro fertilisation (IVF) is linked to an increased rate of relapse among women with multiple sclerosis (MS), suggests a small study published online in the Journal of Neurology Neurosurgery and Psychiatry.

12 Jun 2012